Table 1 Clinical characteristics of patients and characteristics of studies included in the meta-analysis
Study | Country | Study type | Diagnose | Patients (numbers) | Male (%) | Median age (years) | Median time to relapse post-Transplantation (months) | Risk stratification by ELN-2017 | prior HMAs exposure (%) | Treatment protocol | Efficacy (%) | Adverse effects (3/4) (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CR/CRi (%) | ORR(%) | median OS (months) | Survival rate (%) | Thrombocyt- openia | Neutropenia | Neutropenic fever | Infection | |||||||||||
Mittal. et al. 2019 [24] | American | retrospective | AML | 11 | NM | 66 (25–75) | 7 (3–36) | NM | 82 | Ven + AZA (73%); Ven + DEC (27%) Ven + HMAs + DLI (9%) Ven ≥ 14days/cycle; cycles: 3 (1–20) | 36.4 | 82 | 11.0 | 6 months: 81.8 12 months: 36.4 | NM | NM | NM | NM |
Byrne. et al. 2020 [25] | American | retrospective | AML | 16 | NM | 64.3 (34.5–73.7) | 5.7 (0.9–44.9) | Favorable: 6.25% Intermediate: 50% Adverse: 43.75% | NM | Ven + AZA (75%); Ven + DEC (25%) Ven: 14days, 21days or 28days/cycle cycles: 3 (1–11) | 31.3 | 56.3 | 4.3 (2.1–6.5) | 6 months: 18.8 12 months: 6.3 | NM | NM | NM | 56.3 |
Diab.et al 2020 [26] | American | retrospective | AML | 17 | 53 | 62 (31–71) | 6.03 (1.5–28.4) | Favorable: 12% Intermediate: 30% Adverse: 58% | 35 | Ven + AZA (53%); Ven + DEC (47%) cycles: 2 (1–10) | 35.3 | NM | 12.0 | NM | NM | NM | 47.1 | NM |
Bewersdorf. et al. 2021 [27] | American | retrospective | AML/MDS | 33 | 51 | 62 (30–73) | ≤ 12 months (70%) ≥ 12 months (30%) | Favorable: 0 Intermediate: 24% Adverse: 76% | 61 | Ven + AZA (79%); Ven + DEC (21%) Ven + HMAs + DLI (21.6%) cycles: NM | NM | 36.4 | 4.7 (3.8-NR) | 6 months: 48.5 12 months: 42.4 | NM | NM | NM | NM |
Joshi.et al 2021 [28] | American | retrospective | AML | 26 | 48 | 58 (20–72) | 9.0 (2.0–37.0) | Favorable: 3% Intermediate: 35% Adverse: 62% | 41 | Ven + AZA (31%); Ven + DEC (69%) cycles: 1.5 (1–10) | 26.9 | 38.5 | 2.6 (1.1–4.1) | 6 months: 26.9 12 months: 11.5 | 65.5 | 69.0 | NM | 55.2 |
Schuler. et al. 2021 [29] | Germany | retrospective | AML/MDS | 32 | 50 | 54 (30.8–71.5) | 1.8 (0.8–42.9) | Favorable: 13% Intermediate: 20% Adverse: 67% | 66 | Ven + AZA (37.5%); Ven + DEC (59.4%) Ven + AZA + DEC (3.1%) Ven + HMAs + DLI (34.4%) Ven: 21days or 28days/cycle; cycles: 2 (1–19) | 31.3 | 43.8 | 3.7 (2.8–4.6) | 6 months: 37.5 12 months: 21.9 | 81.3 | 96.9 | NM | 71.9 |
Gao.et al 2021 [30] | China | retrospective | AML/MDS | 41 | 54.5 | 44 (14–60) | < 12 months(63.6%) > 12 months (36.4%) | others 47.7% adverse 52.3% | NM | Ven + AZA (93.2%); Ven + DEC (6.8%) Ven + HMAs + DLI (2.3%) Ven: 21days or 28days/cycle; cycles: 2 (1–19) | 34.1 | 38.6 | NM | 6 months: 36.4 12 months: 6.8 | 68.2 | 79.5 | NM | 47.7 |
Ozturk. et al. 2022 [31] | Turkey | retrospective | AML | 30 | 46.7 | 43.1 (20–69) | 8.5 (1.7–47.8) | Favorable: 6.7% Intermediate: 66.7% Adverse: 26.7% | 30 | Ven + AZA (93%); Ven + DEC (7%) cycles: 3 (1–6) | 43.5 | 56.5 | 5.3 (2.6 ~ 8.0) | NM | 78.3 | 82.6 | NM | NM |
Serpenti. et al. 2022 [32] | Italy | retrospective | AML | 11 | 54.5 | 65 (31–72) | 6.5 (0.9–48.1) | Favorable: 27.3% Intermediate: 45.4% Adverse: 27.3% | 73 | Ven + AZA (91%); Ven + DEC (9%) Ven + HMAs + DLI (45.5%) cycles: 3 (1–6) | 27.3 | 36.4 | NM | NM | NM | NM | NM | 27.3 |
Zhao. et al. 2022 [33] | China | retrospective | AML | 26 | 57.7 | 35.2 ± 11.4 | 7.6 (3.2–18.4) | Favorable: 0 Intermediate: 69.2% Adverse: 30.8% | 50 | Ven + AZA + DLI (100%) cycles: 6–8 | 26.9 | 61.5 | 9.5 (2.7–20.3) | 6 months: 53.8 12 months: 50.0 | 100 | 100 | 57.7 | NM |